SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy | MicrobiomeTrials← Back to trialsNCT07096999
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
RecruitingOBSERVATIONAL
Trial Details
Start: 2025-01-23Est. Completion: 2031-01-23
Enrollment target: 60 participants Locations- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Other microbiome trials you might be interested in
Head and Neck CancerHead and Neck Squamous Cell CarcinomaParanasal Sinus NeoplasmsNasopharyngeal CarcinomaOropharyngeal Squamous Cell CarcinomaHypopharyngeal CancerCarcinoma of LarynxOral Squamous Cell CarcinomaSalivary Gland CancerAdenoid Cystic CarcinomaProstate CancerMetastatic Castration Resistant Prostate Cancer
Background:
Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat,…
Bethesda, United StatesEst. completion Oct 1, 2036
Prostate Cancer
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 1…
Homewood, United StatesEst. completion Sep 29, 2028